Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
Bio Pharma Dive
APRIL 16, 2023
The pharma has struck the sector’s second-largest buyout this year, announcing a deal for the developer of an inflammatory bowel disease treatment that’s shown promise in testing.
Let's personalize your content